Amedisys Balance Sheet Health
Financial Health criteria checks 6/6
Amedisys has a total shareholder equity of $1.2B and total debt of $353.2M, which brings its debt-to-equity ratio to 29.4%. Its total assets and total liabilities are $2.1B and $938.7M respectively. Amedisys's EBIT is $208.9M making its interest coverage ratio 8.1. It has cash and short-term investments of $245.5M.
Key information
29.4%
Debt to equity ratio
US$353.21m
Debt
| Interest coverage ratio | 8.1x |
| Cash | US$245.45m |
| Equity | US$1.20b |
| Total liabilities | US$938.68m |
| Total assets | US$2.14b |
Recent financial health updates
Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?
Feb 25
We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt
Jul 20Is Amedisys (NASDAQ:AMED) A Risky Investment?
Feb 20These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely
Nov 18Amedisys (NASDAQ:AMED) Could Easily Take On More Debt
Aug 18Recent updates
Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance
Nov 05Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?
Apr 10Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?
Feb 25Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around
Feb 10At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?
Jan 03A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)
Dec 16Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal
Nov 12Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?
Sep 19An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued
Sep 04Amedisys: ROIC, Tangible Book Value Each Softening
Aug 24Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement
Aug 04Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates
Jul 27We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt
Jul 20At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?
Jun 04Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled
May 05Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?
Apr 20Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?
Apr 06Is Amedisys (NASDAQ:AMED) A Risky Investment?
Feb 20Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue
Jan 19Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?
Dec 03These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely
Nov 18Amedisys (NASDAQ:AMED) Could Easily Take On More Debt
Aug 18Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)
Jul 23Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity
Jul 18Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive
Jun 28It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package
Jun 02Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?
May 24Financial Position Analysis
Short Term Liabilities: AMED's short term assets ($579.9M) exceed its short term liabilities ($486.0M).
Long Term Liabilities: AMED's short term assets ($579.9M) exceed its long term liabilities ($452.7M).
Debt to Equity History and Analysis
Debt Level: AMED's net debt to equity ratio (9%) is considered satisfactory.
Reducing Debt: AMED's debt to equity ratio has reduced from 39.3% to 29.4% over the past 5 years.
Debt Coverage: AMED's debt is well covered by operating cash flow (59.9%).
Interest Coverage: AMED's interest payments on its debt are well covered by EBIT (8.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 06:29 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amedisys, Inc. is covered by 32 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Hoffman | Avondale Partners |
| Matthew Gillmor | Baird |
| Steven Valiquette | Barclays |